SNGX News and Press, Soligenix Inc. From 11/07/22

NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- New to The Street, a nationally syndicated TV show, announces airing its episode #404 on the Fox Business Network tonight, Monday, November 7, 2022, at 10:30 PM PT. New to The Street’s 404 th TV episode features ...

Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses PR Newswire Emerging infectious diseases where n o protective vaccines are currently available SuVax™ targe...

Soligenix Announces Formation of Psoriasis Medical Advisory Board PR Newswire Phase 2a clinical study in mild-to-moderate psoriasis initiating in December 2022 PRINCETON, N.J. , Oct. 25, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq...

NEW YORK, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FMW Media's New to The Street , a nationally syndicated TV show, announces episode #399 airing tonight, Monday, October 24, 2022, at 10:30 PM PT on the Fox Business Network. New to The Street’s 399th TV...

NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- FMW Media's New to The Street / Newsmax TV announces the broadcasting line-up of its nationally syndicated 1-hour TV show this Sunday, October 23, 2022, airing time 10-11 AM ET. New to The Street's 398th TV episode line...

Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting PR Newswire Meeting adjourned to November 17, 2022 , at 9:00 a.m., Eastern Time Soligenix encourages all stockholders as of record July 25, 2022 , who h...

NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- FMW Media Inc.'s New to The Street is pleased to announce that Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, w...

NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- FMW Media Inc.'s New to The Street is pleased to announce that Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, w...

New York, New York--(Newsfile Corp. - October 13, 2022) - PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (NASDAQ: SNGX) is anticipating significant catalysts in Q4 and a potentially transformational year in 2023. Following its successful Phase 3 clinical trial evaluating...

Summary Soligenix is an underfollowed biotech company trading at a $20 million market cap. The company is about to file an NDA for HyBryte, which I expect to become a first-in-class treatment in cutaneous T-cell lymphoma. The company’s heat-stable vaccine development pr...